Figure 5.

Example individual fits for the control (no change in IgE production) and feedback models for a phase I study (Q0673g) in patients with allergic rhinitis. The solid lines are the feedback model, the dashed the control and the symbols are the measured data. On the left is a 49-year-old, 58.5-kg, 152-cm Asian woman with 388 IU ml⁻¹ (931 ng ml⁻¹) baseline IgE given 0.030 mg kg⁻¹ bodyweight per IU ml⁻¹ baseline IgE every 2 weeks for 26 weeks then 0.0015 mg kg⁻¹ per IU ml⁻¹ for 18 weeks. IgE production decreased from 1523 to 216 µg day⁻¹ over 517 days (thick solid line). The decrease in IgE production paralleled the decrease in total IgE. On the right is a 22-year-old, 81.9-kg, 152-cm Asian man with 205 IU ml⁻¹ (492 ng ml⁻¹) baseline IgE, given 0.030 then 0.005 mg kg⁻¹ bodyweight per IU ml⁻¹ baseline IgE every 2 weeks. The model estimated IgE production decreased from 1188 to 859 µg day⁻¹ over 397 days. Omalizumab (); total IgE (); IgE production (—); free IgE ()